Goldman Sachs
PSTV

Goldman Sachs’s Plus Therapeutics PSTV Stock Holding History

Goldman Sachs’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,070
Closed -$9.3K – 6593
2025
Q2 		$9.3K Buy
+1,070
New +$14K ﹤0.01% 6005
2020
Q4 		– Sell
-173
Closed -$166K – 5660
2020
Q3 		$166K Buy
+173
New +$168K ﹤0.01% 4974
2017
Q1 		– Hold
0
– -$27K – 6953
2016
Q4 		– Hold
0
– – – 6562
2016
Q2 		– Hold
0
– -$28K – 7200
2016
Q1 		– Hold
0
– – – 6639
2015
Q4 		– Hold
0
– – – 6835
2015
Q3 		– Hold
0
– – – 6475
2015
Q2 		– Hold
0
– – – 6276
2015
Q1 		– Hold
0
– – – 4826
2014
Q4 		– Hold
0
– – – 5346
2014
Q3 		– Hold
0
– – – 7018
2014
Q2 		– Hold
0
– – – 6703
2014
Q1 		– Hold
0
– – – 6519
2013
Q4 		– Hold
0
– – – 6397
2013
Q3 		– Hold
0
– – – 6379
2013
Q2 		– Hold
0
– – – 6076

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Goldman Sachs's PSTV Position: Q3 2025 in Review

Goldman Sachs sold out of Plus Therapeutics (PSTV) in Q3 2025, closing a stake of 1,070 shares — an estimated $9.3K sold.

Goldman Sachs first reported a position in PSTV in Q3 2020 and held it in 2 quarters. The position peaked at $166K in Q3 2020. 20 funds tracked by Wall St. Rank hold PSTV as of Q3 2025.

  • Goldman Sachs reported no remaining Plus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 1,070 Plus Therapeutics shares in Q3 2025, an estimated $9.3K.
  • Goldman Sachs first reported a position in Plus Therapeutics in Q3 2020 and held it in 2 quarters.
  • Goldman Sachs's Plus Therapeutics position peaked at $166K in Q3 2020.
  • 20 funds tracked by Wall St. Rank held Plus Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.